To investigate cross-resistance of BTZ to the chemotherapeutic agents that were used in the BTZ combination therapy in the TACL study [8, 9], we examined the correlation between BTZ sensitivity and sensitivities to VCR, DNR, Dex, and L-Asp in 79 BCP-ALL cell lines (S4 Table, and Fig 3A and 3B). This evidence concerns the gene CASC3 and acute lymphoblastic leukemia.